Literature DB >> 3111480

Irreversible binding and metabolism of propranolol by human liver microsomes--relationship to polymorphic oxidation.

L Shaw, M S Lennard, G T Tucker, N D Bax, H F Woods.   

Abstract

Studies were performed to investigate the irreversible binding and oxidative metabolism of propranolol in human liver microsomes and the relationship of binding and metabolism to the polymorphic oxidation of debrisoquine. Incubation of microsomes with 14C-labelled propranolol in the presence of a NADPH-generating system gave rise to irreversible binding which increased linearly with time and became saturated at high substrate concentrations. The extent of binding was decreased by the exclusion of cofactors, boiling, anaerobic conditions, and the addition of reduced glutathione and SKF-525A. Trichloropropene oxide had a negligible effect on cofactor-dependent binding. However, debrisoquine, antipyrine and phenacetin decreased binding to a considerable extent. The latter compound abolished cofactor-dependent binding completely at the concentration used (1 mM). Electrophoresis of microsomes which had been incubated with tritiated propranolol revealed that binding was probably occurring to a large number of proteins particularly in the 40,000-90,000 molecular weight range. Glutathione, debrisoquine and antipyrine did not inhibit the 4'-hydroxylation and N-deisopropylation of propranolol. In contrast, phenacetin exerted a very potent inhibitory action on both routes of metabolism. It is concluded that a product or products of propranolol oxidation bind irreversibly but non-selectively to human liver microsomal protein, the enzyme system responsible for the activation of propranolol appears to be related more closely to the cytochrome P-450 system which metabolizes phenacetin than to that metabolising debrisoquine, and radiolabelled propranolol is not a sufficiently specific probe for studying these cytochrome P-450 systems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111480     DOI: 10.1016/0006-2952(87)90592-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.

Authors:  Z E Wilson; A Rostami-Hodjegan; J L Burn; A Tooley; J Boyle; S W Ellis; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

2.  Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Authors:  Nancy Hakooz; Kiyomi Ito; Helen Rawden; Helen Gill; Lynn Lemmers; Alan R Boobis; Robert J Edwards; David J Carlile; Brian G Lake; J Brian Houston
Journal:  Pharm Res       Date:  2006-02-28       Impact factor: 4.200

Review 3.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

4.  Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

Authors:  S V Otton; E M Gillam; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

5.  Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.

Authors:  K Rowland; W W Yeo; S W Ellis; I G Chadwick; I Haq; M S Lennard; P R Jackson; L E Ramsay; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

6.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.

Authors:  S W Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; M S Lennard; C R Wolf; G T Tucker
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

7.  Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the "altered enzyme hypothesis".

Authors:  C Weber; K Stoeckel; D Lalka
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

8.  Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.

Authors:  Edgor Cole Tolledo; Sharon Miksys; Frank J Gonzalez; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2020-01-06       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.